United States Patent 8,609,647: scope of claims and U.S. patent landscape for Janus kinase 2/3 inhibitors
What does US 8,609,647 claim at the center of scope?
US 8,609,647 claims a broad genus of small-molecule compounds defined by formula [I] and expressed through a nested set of substituent variables (Ra, Rb, Rc, Ya/Rc5/p, “Ring T,” and other indices). The claims also include composition and method-of-use coverage, with the methods expressly tied to Janus kinase 2 (JAK2) and Janus kinase 3 (JAK3) inhibition and to a set of inflammatory, immune-mediated, and transplant-related indications.
Core claim structure (Claim 1)
Claim 1 is a “compound of formula [I]” with these definitional blocks:
Substituted positions
- Ra: independently (C1-6 alkyl) or (halogen atom); n1 = 0 to 4
- Rb: independently (C1-6 alkyl) or (halogen atom); n2 = 0 to 4
- m1 = 0 to 3
- m2 = 1 to 4
Linkage / heteroatom / alkene feature
- Xa = Xb = CH═CH
- X is a nitrogen atom
Rc substituent options (central chemical diversity)
Rc is selected from (1) to (6):
- hydrogen
- C1-6 alkyl (optionally substituted by Group A, 1 to 5 substituents)
- —C(═O)—Rc1
- —C(═O)—O—Rc2
- —C(═O)—NRc3Rc4
- a group of formula (defined below)
where each of Rc1, Rc2, Rc3, Rc4 is:
- hydrogen or
- C1-6 alkyl optionally substituted by 1 to 5 substituents selected from Group A
Group formula (the most expansive “tail” element)
Rc “option (6)” includes:
- Ya: C1-6 alkylene OR —C(═O)— OR —C(═O)—O—
- Ring T: (i) C6-10 aryl OR (ii) C3-10 cycloalkyl OR (iii) saturated monoheterocyclyl (1 to 4 heteroatoms chosen from N/O/S; ring size 3 to 7 atoms)
- Rc5: cyano or nitro
- p = 0 to 4
- Group A (substitution options) consists of:
- hydroxyl
- C1-6 alkoxy
- cyano
- C1-6 alkoxycarbonyl
- C1-6 alkylcarbonyloxy
- C2-6 alkenyloxy
Allowed embodiments
- pharmaceutically acceptable salt
- solvate
“Narrowing” dependent claims (Claims 2–13 and selective Rc sub-claims)
Dependent claims apply tighter numerical bounds and narrower Ring/functional preferences:
-
Claim 2: narrows to
- n1 = 0 to 2
- n2 = 0 to 2
- m1 = 0 to 3
- m2 = 1 to 3
- Ring T restricted to phenyl, C3-6 cycloalkyl, or pyrrolidinyl
- Rc restricted to specific patterns of substituted Rc groups
- Rc5 = cyano or nitro
- p = 0 or 1
-
Claim 3: provides a specific index subset:
-
Claims 4–7: define specific “formula [II]–[IV]” and a further index combination set:
- Claim 4: m1 = 1 and m2 = 2 (formula [II])
- Claim 5: m1 = 0 and m2 = 2 (formula [III])
- Claim 6: m1 = 0 and m2 = 1 (formula [IV])
- Claim 7: a set of (m1, m2) combinations:
- (0,3) or (2,1) or (2,2) or (3,2)
-
Claims 8–12: set specific (n1, n2) pairings
- (0,0), (1,0), (0,1), (2,0), (0,2)
-
Claim 13: Ra limited to methyl or fluorine
-
Claims 14–17: constrain Rc to specific carbonyl/amide formats and substitution patterns
- Claim 14: Rc = —C(═O)—Rc1
- Claim 15: Rc1 = C1-6 alkyl optionally substituted by one hydroxyl or cyano
- Claim 16: Rc = —C(═O)—NRc3Rc4
- Claim 17: Rc3 = C1-6 alkyl with one cyano; Rc4 = hydrogen or C1-6 alkyl
Named structural embodiments (Claims 18–49)
Claims 18–49 each recite “The compound as claimed in claim 1 which is represented by the following chemical structural formula” followed by multiple specific structures. These are not reproduced in the user text (the structures render as blanks), but the claim logic is clear:
- each of these claims is a specific compound instance within the genus of Claim 1,
- each is still entitled to salts/solvates,
- and these structure-specific claims then anchor downstream composition and method-of-use claims (Claims 50–95).
What else is covered beyond the compound: compositions and JAK2/JAK3 methods?
The patent adds separate coverage for:
1) Pharmaceutical compositions
2) Methods of inhibiting JAK2 or JAK3
3) Methods of treating or preventing multiple diseases, with explicit indication lists.
Composition claims
- Claim 19: composition with compound of claim 1 + pharmaceutically acceptable carrier.
- Claim 50: composition with compound of claims 34–49 + carrier.
- Claim 81: composition with compound of claims 65–80 + carrier.
Mechanism and use claims
-
Claims 20–22: method of inhibiting JAK2 or JAK3, with dependent options for the specific kinase.
-
Claims 23–27: treating/preventing disease selected from:
- organ transplant rejection
- graft versus host reaction after transplantation
- rheumatoid arthritis
- psoriasis
- dry eye
- atopic dermatitis
-
Claims 28–33: human subject limitations applied to the above method categories.
Structure-specific method coverage
The same method framework is repeated for the structure-specific embodiments:
- Claims 51–54: inhibiting JAK2 or JAK3 for compounds in claims 34–49
- Claims 55–60: disease treatment/prevention for compounds in claims 34–49 (transplant rejection/GVHD; RA; psoriasis; dry eye; atopic dermatitis)
- Claims 61–64: human limitations per indication
- Claims 82–95: identical “inhibition + disease methods” for compounds in claims 65–80 (with human limitations at 83, 86, 89, 92, 95)
How broad is the chemical genus in practical claim-design terms?
Claim 1 uses layered substituent freedom. Even without rendering the full formula images, the allowed variable ranges define a very large deck of possible structures:
Indices and substitution freedom in Claim 1 (quantitative bounds)
- m1: 0–3 (4 values)
- m2: 1–4 (4 values)
- n1: 0–4 (5 values)
- n2: 0–4 (5 values)
- p (on the Rc tail group): 0–4 (5 values)
Fragment diversity
- Ra/Rb: each position can be C1-6 alkyl or halogen.
- Rc:
- multiple carbonyl formats (ketone-like —C(═O)—Rc1, ester-like —C(═O)—O—Rc2, amide-like —C(═O)—NRc3Rc4),
- or a larger “group of formula” that adds:
- Ya linkage (alkylene vs acyl vs acyloxy)
- Ring T size/heteroatom diversity
- Rc5 (cyano or nitro)
- p substitution count (0–4)
- Group A: six functional classes, including both electron-withdrawing (cyano) and H-bonding (hydroxyl, alkoxy).
Claim hierarchy effect: genus plus “hard” instances
This filing pattern is typical of broad genus patents that simultaneously:
- keep a large “catch-all” compound claim (Claim 1),
- constrain specific subsets via dependent claims (Claims 2–17),
- then lock in multiple exact structures (Claims 18, 34–49, 65–80, etc.) that are more resilient in validity challenges because they are not forced to satisfy the entire broad functional variable space as a matter of claim interpretation.
What is the functional target and where is the competitive “hit zone”?
The patent’s method claims are centered on JAK2 and JAK3 inhibition and cover an indication set aligned with JAK-pathway immune modulation:
- organ transplant rejection and GVHD
- rheumatoid arthritis
- psoriasis
- dry eye
- atopic dermatitis
From a competitive standpoint, this drives two practical enforcement realities:
1) If a competitor’s program is a JAK2/JAK3 inhibitor with a close structural match to the claimed genus or to the specific structures in Claims 18 and 34–80, the infringement exposure is concentrated.
2) Even if a compound sits outside Claim 1’s full genus, the structure-specific claims can still create infringement risk if the marketed compound maps to one of the recited structures.
U.S. patent landscape: what this patent likely blocks in a freedom-to-operate (FTO) sense
Based only on the claim text provided, US 8,609,647 is built as a compound-and-use patent:
- Compound coverage: formula genus + several sub-genus subsets + multiple exact structures
- Composition coverage: formulation with pharmaceutically acceptable carriers
- Use coverage: method claims for inhibition of JAK2 or JAK3 and for treatment/prevention of specific diseases
Where overlap risk is highest (claim-logic mapping)
The highest overlap risk sits at the intersection of:
- chemical structure that falls within formula [I] definitions (Claim 1), or
- an embodiment exactly matching a listed structural formula (Claims 18, 34–49, 65–80),
combined with:
- mechanism (JAK2/JAK3 inhibition)
- indication (RA, psoriasis, atopic dermatitis, dry eye, transplant rejection/GVHD)
Practical carve-out effect created by dependent claim narrowing
Dependent claims impose tighter selection rules (e.g., Ring T restricted to phenyl/cycloalkyl/pyrrolidinyl, p restricted to 0 or 1 in Claim 2; specific (m1,m2) pairs in Claims 4–7). If a competitor’s structure differs in those exact dimensions, it may not meet the dependent claims; however, it still may meet Claim 1 if still within the broader genus variable bounds. The real question is thus:
- does the competitor stay within the broad genus variables (Claim 1),
- or does it match one of the enumerated structures (Claims 18, 34–49, 65–80).
Claim-to-infringement pathways: what would be asserted in litigation
The claim set supports three distinct pleading strategies.
1) Direct compound infringement
- Assert Claim 1 against a product containing the patented compound (or its salt/solvate).
- Assert dependent claims (2–17) if the defendant’s compound matches those narrower parameter constraints.
- Assert structure-specific claims (18, 34–49, 65–80) if the product maps to a listed structure.
2) Composition infringement
- Assert composition claims (19, 50, 81) if the defendant sells a formulation using the claimed compound(s).
3) Method-of-use infringement
- Assert the JAK2/JAK3 inhibition and indication claims (20–27 and 51–64 and 82–95) tied to label indications and prescribed use.
Key Takeaways
- US 8,609,647 claims a large genus (Claim 1, formula [I]) for JAK2/JAK3 inhibitors, defined by multi-parameter substituent ranges (n1 0–4, n2 0–4, m1 0–3, m2 1–4, p 0–4) plus extensive functional group options (Group A includes hydroxyl, alkoxy, cyano, alkoxycarbonyl, alkylcarbonyloxy, alkenyloxy).
- The patent combines the genus with multiple enumerated “exact structure” embodiments (Claims 18, 34–49, 65–80), which then anchor composition and method claims that repeat the same indication set (RA, psoriasis, dry eye, atopic dermatitis, transplant rejection/GVHD).
- Enforcement exposure for competitors is highest where a candidate or marketed compound fits Claim 1’s genus or matches one of the listed structures, with additional risk where the marketed use aligns with the explicitly claimed JAK2/JAK3 inhibition and the enumerated indications.
FAQs
1) Is the patent limited to JAK3 only?
No. It covers inhibition of JAK2 or JAK3 (Claims 20–22, 51–54, 82–85), with dependent claims specifying JAK3 or JAK2.
2) What kinds of chemical substitutions are allowed under Claim 1?
Ra/Rb are C1-6 alkyl or halogen; Rc supports hydrogen, alkyl, carbonyl/ester/amide linkages, or a tail with Ring T; p ranges 0–4; and Group A supports hydroxyl, alkoxy, cyano, alkoxycarbonyl, alkylcarbonyloxy, and alkenyloxy.
3) Does the patent cover salts and solvates?
Yes. Claim 1 and the downstream claims cover pharmaceutically acceptable salts and solvates.
4) Which indications are explicitly claimed?
Organ transplant rejection and GVHD after transplantation; rheumatoid arthritis; psoriasis; dry eye; and atopic dermatitis (Claims 23–27 and corresponding structure-specific sets).
5) What is the practical difference between Claim 1 and the structure-specific claims (18, 34–49, 65–80)?
Claim 1 is a broad formula genus; the structure-specific claims recite particular compounds (by structural formula) within that genus and can provide direct mapping to specific products, strengthening infringement theories around enumerated embodiments.
References
[1] United States Patent US 8,609,647 (claim set provided in prompt).
